Cantor Fitzgerald Reaffirms Buy Rating for Omeros Corporation (OMER)
Cantor Fitzgerald restated their buy rating on shares of Omeros Corporation (NASDAQ:OMER) in a research note released on Friday. They currently have a $21.00 price target on the biopharmaceutical company’s stock.
Several other equities research analysts have also recently weighed in on the stock. FBR & Co reaffirmed a buy rating on shares of Omeros Corporation in a research report on Thursday, November 10th. Needham & Company LLC cut their price objective on shares of Omeros Corporation from $28.00 to $24.00 and set a buy rating for the company in a research report on Thursday, November 10th. Maxim Group set a $19.00 price objective on shares of Omeros Corporation and gave the stock a buy rating in a research report on Wednesday, November 2nd. Wedbush reaffirmed an outperform rating and set a $56.00 price objective on shares of Omeros Corporation in a research report on Friday, October 21st. Finally, Zacks Investment Research raised shares of Omeros Corporation from a sell rating to a hold rating in a research report on Wednesday, October 19th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $34.52.
Shares of Omeros Corporation (NASDAQ:OMER) opened at 13.75 on Friday. Omeros Corporation has a 12 month low of $7.20 and a 12 month high of $16.80. The firm’s market cap is $590.08 million. The stock’s 50 day moving average is $9.49 and its 200 day moving average is $10.83.
Omeros Corporation (NASDAQ:OMER) last posted its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.06. The firm had revenue of $11.30 million for the quarter, compared to the consensus estimate of $11.64 million. During the same period in the prior year, the company earned ($0.53) EPS. The company’s revenue for the quarter was up 253.1% compared to the same quarter last year. Analysts forecast that Omeros Corporation will post ($1.68) EPS for the current fiscal year.
In other news, VP Marcia S. Kelbon sold 16,000 shares of the company’s stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $10.91, for a total value of $174,560.00. Following the completion of the transaction, the vice president now owns 179,597 shares of the company’s stock, valued at $1,959,403.27. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 13.60% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sheaff Brock Investment Advisors LLC purchased a new position in Omeros Corporation during the second quarter valued at about $105,000. BlackRock Group LTD increased its position in Omeros Corporation by 4.5% in the third quarter. BlackRock Group LTD now owns 12,440 shares of the biopharmaceutical company’s stock valued at $139,000 after buying an additional 540 shares in the last quarter. Bourgeon Capital Management LLC purchased a new position in Omeros Corporation during the second quarter valued at about $158,000. BlackRock Advisors LLC increased its position in Omeros Corporation by 1.0% in the second quarter. BlackRock Advisors LLC now owns 17,415 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 173 shares in the last quarter. Finally, Mesirow Financial Investment Management Equity Management purchased a new position in Omeros Corporation during the second quarter valued at about $244,000. 51.86% of the stock is owned by institutional investors.
Omeros Corporation Company Profile
Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.
Receive News & Stock Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related stocks with our FREE daily email newsletter.